Castle Biosciences Inc Environmental Analytics
Environmental and financial analysis dashboard for Castle Biosciences Inc. Industry: MANUFACTURING
Company Overview for Castle Biosciences Inc
Highlights
Showing data for FY2022
Operational Environmental Cost
$0.49m
Operational Environmental Cost Intensity
0.36%
Total Environmental Cost
N/A
Total Environmental Cost Intensity
N/A
ΔOperational Environmental Cost (2020-2022)
$-0.04m
Decoupling Rate (2020-2022)
35%
Adjusted EBITDA
$-59m
Adjusted EBITDA Margin
-43%
Environmental cost statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| -47.41% | 27.92% | 68.77% | ||
| 0.29% | 0.10% | 0.09% | 0.09% | |
| -21.55% | 34.86% | 81.19% | ||
| 0.56% | 0.29% | 0.27% | 0.30% | |
| $1m | $0m | $0m | $1m | |
| -30.40% | 33.06% | 78.10% | ||
| 0.85% | 0.39% | 0.36% | 0.40% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
| N/A | N/A | N/A | ||
| N/A | N/A | N/A | N/A | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2022
Integrated financial analysis
Highlights
Showing data for FY2022
Adjusted EBITDA Margin
-43%
Adjusted EBIT Margin
-51%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2022
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$63m | $94m | $137m | $220m | |
| 50.18% | 45.65% | 60.38% | ||
$70m | $131m | $195m | $265m | |
| 111.32% | 138.91% | 142.57% | 120.49% | |
$-7m | $-37m | $-58m | $-45m | |
| -11.32% | -38.91% | -42.57% | -20.49% | |
$-8m | $-40m | $-69m | $-57m | |
| -12.08% | -42.53% | -50.27% | -26.10% | |
| ENVIRONMENTAL COST DATA | ||||
$1m | $0m | $0m | $1m | |
| 0.85% | 0.39% | 0.36% | 0.40% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$-8m | $-37m | $-59m | $-46m | |
| -12.17% | -39.30% | -42.93% | -20.88% | |
$-8m | $-40m | $-69m | $-58m | |
| -12.92% | -42.92% | -50.63% | -26.49% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2022
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.09%
Scope 2 (% of Sales)
0.27%
Operational Environmental Cost Intensity
0.36%
Scope 3 (% of Sales)
N/A
Total Environmental Cost Intensity
N/A
Selected peer group
Showing data for FY2022
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Castle Biosciences Inc | US | $0m | 0.36% |
Loading similar companies data...
Industry distribution
Showing data for FY2022
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2022
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | N/A | N/A | N/A | N/A |
Energy-related activities (3) | N/A | N/A | N/A | N/A |
Upstream transportation (4) | N/A | N/A | N/A | N/A |
Waste (5) | N/A | N/A | N/A | N/A |
Business travel (6) | N/A | N/A | N/A | N/A |
Commuting (7) | N/A | N/A | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | N/A | N/A | N/A | N/A |
Processing of products (10) | N/A | N/A | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | N/A | N/A | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $0m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2022